What Reckitt and Haleon Q1 2026 said
Both UK-listed consumer health majors reported Q1 2026 in late April. Both flagged a soft cold and flu season as a meaningful drag.
Reckitt reported Core LFL net revenue growth of 1.3% (per the Reckitt Q1 2026 trading update, with detail in Investing.com earnings-call coverage). Excluding seasonal OTC the figure was 3.1%. Emerging Markets grew 7.6% LFL to £1,087m, led by Dettol, Gaviscon and vitamins/minerals/supplements. Mead Johnson Nutrition fell 2.7% LFL to £531m (volume down 6.8%, price/mix up 4.1%). FY 2026 guidance reaffirmed at 4 to 5% Core LFL. The £1 billion share buyback continues with £669m completed by 17 April 2026.
Haleon reported group organic revenue growth of 2.2% (per the Haleon Q1 2026 trading statement, summarised in Investing.com Q1 slides coverage). Pain Relief was essentially flat at -0.3% organic on £654m sales. Within Pain Relief, Advil outperformed in North America driven by the "No Pain More Gain" campaign. Voltaren and Panadol grew in select geographies. Oral Health was the standout segment for Haleon at group level.
The UK OTC analgesics players
Reckitt (Nurofen, Lemsip, Strepsils, Gaviscon). Per Wikipedia, FY 2025 group revenue was £14.2 billion with operating income of £4.2 billion and net income of £3.2 billion. Listed on London Stock Exchange (RKT), FTSE 100 component. Headquartered in Slough, UK. Reckitt's UK OTC portfolio extends beyond Nurofen into cold and flu (Lemsip, Strepsils) and digestive (Gaviscon). The breadth means Q1 reads are a blended signal across pain plus cold/flu plus digestive.
Haleon (Panadol, Voltaren, Advil, Excedrin). Per Wikipedia, Haleon was established 18 July 2022 as a corporate spin-off from GSK. FY 2025 revenue £11.0 billion. Listed LSE and NYSE (HLN), FTSE 100. Headquartered in Weybridge, UK. Pain Relief is one of five core Haleon categories (alongside Oral Health, Vitamins/Minerals/Supplements, Respiratory Health, Digestive Health and Other).
Kenvue (Tylenol, Motrin, Benadryl, Imodium). Per Wikipedia, FY 2025 revenue US$15.1 billion. Spun off from Johnson & Johnson, announcement November 2021. NYSE: KVUE. Headquartered in Summit, New Jersey. Tylenol anchors the US pain market; UK presence is lower than Reckitt or Haleon.
Private label (Boots, Tesco, Sainsbury's, Asda) holds meaningful share in UK paracetamol and ibuprofen tablets at the value tier. A fetchable redistribution-clean share figure is not on file; this section will be expanded once a NielsenIQ thought-leadership or Mintel summary URL is integrated.
Pharmacy channel. Boots and the independent pharmacy network are the channel anchor for UK OTC, differentiating UK from the US grocery-dominated OTC channel mix. Pharmacist-recommended status is the distinct UK competitive lever for branded analgesics.
The Q1 cold and flu season as a structural read
A soft seasonal incidence is the common thread across Reckitt and Haleon Q1 2026. Reckitt explicitly attributes the 1.3% Core LFL to "very low seasonal incidence, weak categories in Europe and geopolitical disruption". Haleon's 0.3% Pain Relief decline includes the same seasonal effect, partially offset by Advil campaign-driven outperformance.
The commercial implication: 2026 brand investment cycles are running on the assumption of mean-reversion in cold and flu incidence. If H2 2026 normalises, Q3 and Q4 should rebuild the consumer-health volume base. If H2 stays soft, both companies face a structural rather than cyclical headwind.
Innovation and brand-investment moves
Reckitt is shipping "Mucinex 12 hour Cold and Fever" in North America from June 2026 (per the Reckitt Q1 trading update). The recovery thesis assumes innovation supports the bounce when seasonal demand normalises.
Haleon's "No Pain More Gain" Advil campaign drove Q1 outperformance in North America (per Investing.com Haleon Q1 slides coverage). The campaign's translation to UK Voltaren and Panadol activity is the watch item for Q2.
What to watch in Q2 and H1 2026
- Whether the cold and flu category normalises in Q3 and Q4, with Mucinex 12-hour innovation supporting Reckitt's recovery thesis
- Whether Haleon Pain Relief recovers above flat in Q2 (current -0.3% Q1 organic)
- UK private-label paracetamol and ibuprofen share trends through Q2 and Q3
- Mead Johnson Nutrition direction at Reckitt (currently -2.7% LFL in Q1)
- Boots channel dynamics and Pharmacist-recommended brand activity
- Whether the £1 billion Reckitt buyback completes on schedule (£669m completed by 17 April 2026)